Blood test marker study for liver cancer linked to hepatitis B
Part of Cancer, Infections clinical trials.
This study looks at a substance called SNHG15, measured to see if it can help identify liver cancer related to hepatitis B. It will compare people with hepatitis B–associated liver cancer to healthy controls and checks for how well this marker fits real-world patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be either a person with hepatitis B–associated liver cancer, or a healthy control who matches the patient group by age and sex
- Have no known tumors anywhere else in the body or in the blood system (for controls and patients as described)
- Controls should not have any non-cancer liver (benign) diseases
- There should be no inflammatory (ongoing inflammation) diseases elsewhere in the body
- Have normal heart, kidney, and liver function based on study screening
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new blood test to help detect liver cancer (HCC) or confirm it’s not present in people with cirrhosis who are being monitored. It may help improve how doctors screen for liver cancer and decide who needs further imaging or treatment.
This study looks at hepatitis B “pgRNA” in blood to see if it can predict long-term outcomes in people with chronic hepatitis B who are treated with antiviral medicines. It may help doctors better forecast risk and guide follow-up over time.
This study tracks chronic hepatitis B patients who have a family history of liver cancer to understand their risk. It tests how well current antiviral treatments work in this group.
This study looks for a new blood marker that may predict how well liver cancer will respond to radiation and what outcomes to expect. It’s for people with hepatitis B–related liver cancer who can safely receive radiation to the liver tumor.
This study is testing a new blood test to see if it can help diagnose liver cancer (hepatocellular carcinoma) early in people with liver damage. If you have cirrhosis (scarring of the liver) or hepatitis B, your participation could help improve how we detect liver cancer.
This study looks at the genes of people with chronic hepatitis B (HBV) to find why some people's immune cells (B cells and NK cells) stop working properly. The goal is to discover new ways to treat the disease.
Hear when a new HCC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.